Methods To Treat Fatty Liver Disease
Background:
The National Cancer Institute's Laboratory of Metabolism is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize therapeutics for fatty liver disease.
Technology:
Currently, there are no adequate therapies for fatty liver disease,
the most prevalent liver disease in the United States. Fat-Specific
Protein 27 (FSP27) expression is regulated by PPAR??, a gene known
to play a critical role in the development of fatty liver.
Over-expression of FSP27 results in an increase in triglyceride
accumulation and an increase in cystolic vacuoles containing lipid
droplets which are associated with development of fatty liver
disease or hepatic steatosis. This abnormal retention of
lipids in liver cells occurs in diabetes and alcoholism and is
correlated with decreased liver function which can often lead to
cirrhosis and sometimes death.
The inventors have discovered that an shRNA directed against FSP27
inhibits fatty liver. This invention could potentially lead to the
development of a new shRNA based therapy for fatty liver disease.
This invention also describes methods of inhibiting FSP27 using
antisense compounds, small molecule inhibitors and antibodies that
target FSP27.
Further R&D Needed:
- Develop new methods of delivery for the shRNA
- Optimize shRNA inhibitors of FSP27 and test them in additional
animal models
R&D Status: Preclinical
IP Status: U. S. Provisional
Application No. 61/043,330 filed 08 April 2008
Value Proposition: Ability to inhibit
Fat-Specific Protein 27 (FSP27)
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #784
Revised 1/12/2008